- Home
- CYTH
as 07-26-2024 4:00pm EST
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | GAINESVILLE |
| Market Cap: | 35.5M | IPO Year: | N/A |
| Target Price: | $3.20 | AVG Volume (30 days): | 42.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.89 - $2.12 | Next Earning Date: | 08-12-2024 |
| Revenue: | $1,126,444 | Revenue Growth: | -15.51% |
| Revenue Growth (this year): | 28.3% | Revenue Growth (next year): | 14.19% |
Latest Cyclo Therapeutics Inc. News
CYTH Breaking Stock News: Dive into CYTH Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
GlobeNewswire
a month ago
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
Business Wire
2 months ago
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
Business Wire
2 months ago
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Simply Wall St.
4 months ago
Pleasing Signs As A Number Of Insiders Buy Cyclo Therapeutics Stock
Business Wire
4 months ago
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Business Wire
4 months ago
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
GlobeNewswire
4 months ago
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
Compare CYTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYTH Cyclo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.